Brian Hoh, MD, MBA’s Post

We have successfully dosed the first patient in our clinical trial of AMT-260 in temporal lobe #epilepsy, representing an important milestone for uniQure and our third clinical trial initiation over the past six months. Nearly one-third of people experiencing focal onset seizures do not respond to currently available treatments and are left with limited therapeutic options – AMT-260 has the potential to be a transformative treatment option for these patients. https://lnkd.in/etfxiHbV

Experience Precision & Speed with QuidelOrtho - EMEA VITROS Systems! When it comes to clinical laboratory testing, every result matters! The VITROS Systems deliver fast, accurate, and reliable results for clinical chemistry and immunoassays, ensuring your lab stays ahead. Key Features of VITROS:  -Dry-slide technology for accurate results with minimal interference -Broad test menu covering a wide range of diagnostics -Advanced automated workflow to reduce human error -Low sample volume, ideal for pediatric and elderly patients -Built-in quality control and real-time error detection Clinical Lab Testing Tip: Did you know that early detection through accurate CL testing can improve patient outcomes in areas like cardiac health, liver function, and infectious disease? Discover how VITROS empowers your lab to deliver results that save lives! #HVD #HVDEgypt #Lifesciences #Healthcare #ClinicalTesting #QuidelOrtho #VITROSSystems #Diagnostics #LabInnovation #HealthcareTech #ReliableTesting #Immunoassays #ClinicalChemistry

Routine Stress Testing After PCI in Patients With and Without Acute Coronary Syndrome A Secondary Analysis of the POST-PCI Randomized Clinical Trial: @JAMACardio Routine stress testing within the first year post PCI? Summary 👇 👇 👇 https://lnkd.in/eZJE3cc4

In patients with primary hyperparathyroidism, first-line F18-choline PET/CT is a suitable and safe replacement for MIBI SPECT/CT, finds randomized clinical trial. https://ja.ma/4c6v0Hx

At EE, we believe that people with #cysticfibrosis deserve to be informed of all research and clinical trial opportunities so they are equipped to make the best decisions for themselves. This is the driving force behind our patient registry and our ongoing work to connect potentially eligible individuals with #CF to relevant clinical trials. If you or your child does not benefit from CFTR modulators, sign up to join our registry and get the latest updates on relevant CF clinical trials – sent directly to your inbox! Join EE’s Patient Registry >>> https://bit.ly/3ThVfm7 #CysticFibrosisAwareness #CFResearch #RareDisease #ClinicalTrials #PatientRegistry

✨ Bioxodes meets a milestone – 16th patient enrolled in BIOX-101 trial. ✨ Bioxodes has enrolled patient nr 16 in a clinical trial with BIOX-101 in hemorrhagic stroke, marking a major milestone that will trigger an interim data analysis. Across 10 stroke units in Belgium, we are testing BIOX-101, a therapy designed to limit the damage from intracerebral hemorrhagic stroke (ICH), developed from tick saliva. ICH is an often deadly disease for which there is no available medication. It causes some 40% of all stroke-related deaths, even though it makes up only 13% of all strokes. We expect our interim report by March 2025, an important next step in our mission of offering a breakthrough hope for hemorrhagic stroke patients. Full press release 👉 https://lnkd.in/d_rW9auU BioWin Brussels South Charleroi BioPark #strokecare #voiceofstroke #clinicaltrials #biotech #healthcare #innovation

Novel CAR T Cell Demonstrates High Response Rates in Adult Advanced B-Cell ALL Patients 🔗 https://bit.ly/3VvQmYE “Patients with B-cell ALL need effective standalone treatment options, and obe-cel demonstrated strong long-term efficacy and response rates in patients treated on the FELIX study,” Jabbour said. “Until now, these patients had limited treatment options. We observed minimal immunotoxicity and a strong persistence of CAR T cells, which support obe-cel being the standard of care for this population.”

In a randomized clinical trial of COVID-19 rebound following antiviral treatment, viral and symptom rebound were both common and not statistically different after treatment with either VV116 or nirmatrelvir–ritonavir in patients with mild-to-moderate COVID-19. https://ja.ma/3VjqPm2

Bioxodes meets a milestone – 16th patient enrolled in BIOX-101 trial. ✨ Bioxodes has enrolled patient nr 16 in a clinical trial with BIOX-101 in hemorrhagic stroke, marking a major milestone that will trigger an interim data analysis. Across 10 stroke units in Belgium, we are testing BIOX-101, a therapy designed to limit the damage from intracerebral hemorrhagic stroke (ICH), developed from tick saliva.

Today, Ocugen announced positive preliminary efficacy and safety data from the Phase 1 dose-escalation portion of the Phase 1/2 OCU410 ArMaDa clinical trial for geographic atrophy.  https://bit.ly/4fWAeXF The preliminary OCU410 data, along with data from the Phase 1/2 OCU410ST GARDian clinical trial for Stargardt disease and data on Leber congenital amaurosis (LCA) from the Phase 1/2 OCU400 clinical trial were presented during last week’s clinical showcase, which is now available on the Ocugen website https://bit.ly/490Nmc0